2025 has been a stellar year for ZymoChem. In February, the California-based biochemicals company announced a successful commercial-scale demo for its biodegradable super-absorbent polymer.
The following month came a partnership with Lululemon, arguably the world’s best-known athleisure brand.
By the fourth quarter, it had been named startup of the year by the International Textile Manufacturers Federation.
We take stock of ZymoChem’s achievements and the strategic factors driving its success.
Lululemon lends scale-up support
Moisture-wicking, fast-drying, light, and stretchy: plastic fibres combine properties that sportswear demands and which no other scaled materials deliver. Yet manufacturing them releases huge amounts of greenhouse gases, presenting an industry-wide problem: how to eliminate synthetics without compromising function.
The Lululemon-ZymoChem tie-up of March 2025 aims to find a way out of the impasse. Lululemon is looking to do this by helping ZymoChem scale its biobased adipic acid.
Adipic acid is a key ingredient in manufacturing nylon 6,6, a type of nylon popular among sportswear manufacturers for its durability. Making conventional adipic acid from petroleum releases a greenhouse gas called nitrous oxide. This is a gas that warms the planet far more quickly than carbon dioxide if released into the atmosphere.
ZymoChem’s biobased adipic acid, meanwhile, has far lower ‘global warming potential’, meaning the amount of heat trapped by greenhouse gases from product manufacture.
With Lululemon’s support, ZymoChem should be able to expand production for its biobased adipic acid. In turn, Lululemon will gain access to a steady supply of the biobased acid to work into its products.
This is not the first time that Lululemon and ZymoChem have crossed paths: the athleisure-wear brand invested in the startup’s series A funding round in January 2024.
This most recent partnership promises to be a lucrative collaboration – Lululemon has reported that 30% of the material it uses in its products is nylon. Take-offs with global brands like these are often the surest route to kickstarting major expansion for biobased producers.
Picking the right products
The Lululemon tie-up also tells us a lot about ZymoChem’s winning strategy: a combination of its laser focus on strategic markets and foundational problems within sustainable manufacturing.
The company has been highly selective about the products and markets it works in, targeting widely-used yet environmentally damaging chemicals where there are no viable scaled alternatives.
Few materials fit this profile better than nylon, a fossil-based plastic fibre that made up 5% of the global fibre market in 2023 (amounting to 6.7 million tonnes). Despite the high emissions associated with manufacturing, nylon remains a widely used material due to its low cost and high performance.
Biobased alternatives will be an important way to ease this fossil reliance: recycled nylon makes up just 2% of the global market thanks to the high costs of collection, sorting and processing. ZymoChem is looking to fill the gap.
Fermented nappies
ZymoChem is now moving beyond the textiles market. In February 2025, the company made a major product announcement – it had reached commercial scale production for its biodegradable Super Absorbent Polymer (SAP), brand-name BAYSE.
SAPs are some of the hidden base chemicals of the modern economy – these substances can absorb thousands of times their weight in water, a function that makes them indispensable across sectors. Though mostly found in nappies and sanitary pads, they are also useful in certain construction and agriculture applications.
The company says it has achieved multi-metric tonne production levels with its precision fermented version. It also claims to have maintained the same productive efficiency it achieved at the lab level – an impressive feat given the difference in scale between lab and commercial production.
Yet even while striking out, the company is still sticking to its same product selection criteria.
Synthetic, fossil-based SAPs are in wide use but have huge negative side effects for both health and environment.
This is because most are made from petrochemical derivatives, making them emissions intensive. They also do not biodegrade safely, if at all, thanks to their chemical structure.
Finally, they are also a potential trigger for allergic reactions. SAPs are now facing increasing scrutiny from health experts, regulators, environmentalists, and industry want alternatives.
All this marks out a product with a lucrative market for sustainable replacements, just like with nylon precursors.
Precision fermentation on a shoestring
ZymoChem’s big sell is its technical capabilities in precision fermentation. This is a manufacturing process where genetically programmed bacteria consume and metabolise ordinary inputs like plant matter and turn them into complex chemicals – in this case, highly absorbent biopolymer. No petroleum is needed.
Precision fermentation is why ZymoChem’s products can claim minimal environmental impacts. However, sustainability can only ever be one part of the equation for a company intent on scaling.
The other factor has to be cost: few industry clients will buy materials based on their environmental credentials alone, particularly in a global business environment wracked by uncertainty.
Yet bringing down costs in the field of sustainable chemicals is no easy task. In our current economic setup, cost-effectiveness and environmental soundness rarely, if ever, coincide. Fossil fuels and derivative chemicals have already achieved vast economies of scale, not to mention government subsidies and locked-in processing infrastructure.
The cost advantages enjoyed by legacy chemicals are especially clear in the case of synthetic precursors (like conventional adipic acid), which are already cheap to manufacture because they are usually the byproducts of petroleum refining.
This means that if biobased producers are to compete with fossil incumbents, they must be ruthless in managing operating costs. One route to lower-cost precision manufacturing is optimising strains. This means genetically programming workhorse microbes to ramp up their productivity, in other words, capable of producing more target chemicals using the same amount of inputs.
ZymoChem has been busy in its microbe optimisation, designing its organisms to conserve carbon where others would lose it into the air as waste. This, says the company, allows for 50 per cent higher yields compared to current best-in-class biomanufacturing.
Apart from fine-tuning the microbes, producing chemicals in larger facilities can bring down costs dramatically. So can managing electricity demand. Agitators, chillers, and air compressors suck up around 70% of total energy demand in precision fermentation facilities.
In all likelihood, ZymoChem will bring down costs further through a combination of tools: expanding into bigger facilities – something dependent on securing offtakes – making energy demand efficiencies, and tweaking the genetic code of their industrial microbes.
Government as angel investor
ZymoChem’s 2025 achievements all build on a decade’s worth of R&D, demos, and fundraising.
Industry observers could be forgiven for assuming that the seed financing round is where commercialisation begins. However, this is far from the case for biotech firms. The pre-seed is the time they must demonstrate a viable manufacturing process for investors. This demands lots of capital – a tall order for most early startups.
Seed funding often comes after years of graft and ZymoChem was no exception: its first investor round came late in 2021, 6 years after formally incorporating.
Luckily, ZymoChem in its earlier years had the backing of a major investor that counts among the most risk-tolerant in the world: the US Department of Energy. Unlike many private entities, government agencies have the luxury of time. Being under no pressure to make immediate returns on their investment, government backers have the resources and freedom to bring promising startups to maturity over a longer timespan.
The agency backed the company at almost every step. In 2015, just two years after it was founded, the startup received $250, 000 from the government body, as well as an additional $100, 000 from the US Department of Agriculture. In 2020, after a period of robust growth, the company received a $1.1 million grant from the Department and then another $4.2 million in 2021.
This funding was essential for ZymoChem in its early years before private investment flows filled in for public funding, underlining the importance of policy in nurturing biobased winners.
Winning strategies
Of course, all the public funding in the world would be meaningless without a clear strategy. ZymoChem’s has revolved around achieving cost competitiveness and specialising in just a few choice products.
What unites ZymoChem’s products is that they are all biobased alternatives to popular synthetic substances used across multiple industries. Practically, this is a safer way for a biobased startup to maintain revenue through cyclical downturns. Their focus on foundational chemicals also makes them better placed to snap up the big brand deals that can build scaling momentum.
In addition to selecting products with the widest reach, a relentless focus on cost has characterised ZymoChem’s strategy. This will only become more important as its biobased products make inroads into more fossil-dominated sectors.
Right now, few in the precision fermented space can match ZymoChem’s laser focus on scaling and cost-cutting. This puts the company on a secure footing longer term. As the sustainable investment boom of the pandemic years recedes and economic uncertainty persists, cost will become an even bigger factor in how industry buyers and end-consumers weigh up products.